Rafarma pharmaceutical updates: registration of Rafarma microspheres in South Korea

Rhea-AI Summary

Rafarma Pharmaceuticals (OTC: RAFA) announces its participation in a scientific conference focused on radioembolization using Yttrium 90 microspheres for cancer treatment at Severance Hospital in Seoul, South Korea. The nanostructured microspheres are primarily aimed at liver cancer but can also treat other solid tumors. Rafarma is in the process of registering these microspheres in South Korea, the only Asian country using this technology for liver cancer patients under health insurance. Key benefits include minimally invasive procedures, targeted tumor destruction, and improved patient outcomes. Statistics show an increase in average survival from 13 to 27 months and an 89% positive treatment response rate among patients.

Positive

• Rafarma Pharmaceuticals is in the process of registering its Yttrium 90 microspheres in South Korea, opening a new market for pharmaceutical distribution.
• The nanostructured microspheres have shown to increase patient survival from 13 to 27 months when combined with chemotherapy.
• 89% of patients have a positive response to treatment with Rafarma's microspheres, and 27% experience a decrease in tumor size.

Negative

• None.

Sheridan, Wyoming, USA, July 04, 2024 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA) - Rafarma Pharmaceuticals is pleased to announce its participation in the scientific conference on radioembolization using Yttrium 90 microspheres for the treatment of cancer at Severance Hospital in Seoul, South Korea. It is one of the largest university hospitals in South Korea and is of strategic importance to the country.

Currently, procedure is underway to register Yttrium 90 microspheres produced by Rafarma in South Korea, with a view to their subsequent pharmaceutical distribution in Korea. South Korea is the only Asian country with health insurance to use yttrium 90 microspheres for liver cancer patients.

Nanostructured Rafarma microspheres are intended for the treatment of liver cancer, and can also be used for radioembolization of other solid tumors.

Rafarma develops and implements a variety of radionuclide therapy technologies for the treatment of liver cancer and other solid tumors, which can provide a higher quality of life for the patient and delay the development of the disease.

The main idea of ​​radionuclide therapy is the delivery of radioactive isotopes directly to the tumor and its subsequent destruction by ionizing radiation. Similar treatment technologies with different methods of delivering radionuclides have been successfully used to treat various diseases.

The principle of action of microspheres: embolization (blockage) of tumor vessels; selective accumulation in the tumor and its destruction by targeted irradiation; microspheres with Yttrium-90 are administered intra-arterially, which ensures that the maximum number of tumor foci is affected, so it is advisable to use them for the treatment of metastases.

Advantages of using microspheres: minimally invasive administration process; minimal damage to healthy tissue; damage to all foci and metastases of the tumor at once; the ability to deliver almost any dose of radiation to the tumor.

Efficiency of use: the average survival of patients when using microspheres with yttrium and chemotherapy increased from 13 to 27 months compared with the use of chemotherapy alone; 89% of patients have a positive response to treatment; 27% experience a decrease in tumor size.

ABOUT RAFARMA PHARMACEUTICALS

Rafarma Pharmaceuticals is a diversified pharmaceutical company dedicated to the new treatments and solutions development for patients in various fields. Regularly cooperating with leading research institutes and pharmaceutical companies around the world, the business has earned a reputation as a reliable manufacturer and distributor. Rafarma Pharmaceuticals has more than 25 programs in molecular biology, nuclear medicine, immunology, sustainable packaging, and many other fields at the moment.

For more information, please visit https://www.noyarp.com

CONTACTS:
RAFARMA PHARMACEUTICALS
babenko_press@rafapharm.com
+1 (307) 218-0292
Sheridan, Wyoming, 82801, USA

Source: Rafarma Pharmaceuticals, Inc.

FAQ

What is the focus of Rafarma Pharmaceuticals' recent participation in a scientific conference?

Rafarma Pharmaceuticals participated in a scientific conference on radioembolization using Yttrium 90 microspheres for cancer treatment at Severance Hospital in Seoul, South Korea.

What is Rafarma Pharmaceuticals' stock symbol?

Rafarma Pharmaceuticals' stock symbol is RAFA.

What are Yttrium 90 microspheres used for?

Yttrium 90 microspheres are used for the treatment of liver cancer and can also be used for the radioembolization of other solid tumors.

Which country is Rafarma Pharmaceuticals registering its Yttrium 90 microspheres in?

Rafarma Pharmaceuticals is registering its Yttrium 90 microspheres in South Korea.

What is the average survival increase for patients using Yttrium 90 microspheres combined with chemotherapy?

The average survival increase for patients using Yttrium 90 microspheres combined with chemotherapy is from 13 to 27 months.

What is the response rate of patients treated with Rafarma's Yttrium 90 microspheres?

89% of patients treated with Rafarma's Yttrium 90 microspheres have a positive response.